Clinical Trials Logo
  1. Home
  2. Nash
  3. NCT01269320

Natural Soybean-derived Femarelle ®for Patients With Non Alcoholic Fatty Liver Disease

Nash Clinical Trial

Clinical Trial Summary

This is a Single -arm, open-label, before-and after exploratory trial of 90 days of Femarelle ® to improve NAFLD and the metabolic syndrome.

Ingestion of Femarelle will improve non alcoholic steatohepatitis and the metabolic syndrome in patients suffering from these conditions.

Subjects will receive treatment with Femarele 530 mg (1 capsule twice a day) for 90 days and will then be monitored off study treatment for an additional 4 weeks.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01269320
Study type Interventional
Source Hadassah Medical Organization
Contact
Status Withdrawn
Phase Phase 4
Start date January 2012
View Details
See also
  Status Clinical Trial Phase
Active, not recruiting NCT05479721 - LITMUS Imaging Study
Recruiting NCT06308757 - Role of the Very Low Calorie Ketogenic Diet (VLCKD) in Patients With Non-Alcoholic Steatohepatitis (NASH) With Fibrosis N/A
Completed NCT02923154 - Efficacy and Safety of MT-3995 in Patients With Non-Alcoholic Steatohepatitis(NASH) Phase 2
Withdrawn NCT03980912 - Validation of the LiverFASt Test and the Associated Fibrosis Staging Scores Compared to Liver Tissue Pathology Via Liver Biopsy
Terminated NCT04565717 - A Study of ALN-HSD in Healthy Adult Subjects and Adult Patients With Nonalcoholic Steatohepatitis (NASH) Phase 1
Recruiting NCT04302051 - Assessment of Fatty Liver With Thermo-acoustic Device
Recruiting NCT05327127 - Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis Phase 2
Completed NCT06348706 - Effect of Dipeptidyl Peptidase- 4 Inhibitors on Non-Alcoholic Steatohepatitis and Type 1 Diabetes Phase 3
Recruiting NCT05935488 - Early Liver Disease Breath Detection
Active, not recruiting NCT06315361 - DIAbetes and NAFLD
Completed NCT03187496 - Drug-drug Interaction Study Between EDP-305, Midazolam, Caffeine and Rosuvastatin in Healthy Volunteers. Phase 1
Recruiting NCT04442334 - The European NAFLD Registry
Recruiting NCT06338969 - The Impact of Different Carbohydrate Restriction After a Gastric Bypass on the Ketosis and Ketoacidosis N/A
Completed NCT05193916 - A Phase II Clinical Trial of Chiglitazar for NASH Phase 2
Active, not recruiting NCT05669677 - Study to Determine the Response to COVID-19 Vaccination and Prevalence of COVID-19 in Subjects With Chronic Liver Disease
Not yet recruiting NCT04783116 - Plant Stanols and Liver Inflammation in Overweight and Obese Children N/A
Recruiting NCT06193629 - A Multicenter, Double-blind, Placebo-randomized Controlled Clinical Study on the Treatment of Non-alcoholic Steatohepatitis With Tibetan Drug Langqing Atar N/A
Completed NCT04006145 - A Phase 2 Study of Elobixibat in Adults With NAFLD or NASH Phase 2
Recruiting NCT04232293 - Screening of Liver Fibrosis Using Blood Tests in Patients With Type 2 Diabetes Mellitus N/A
Recruiting NCT06410924 - A Study to Evaluate DD01 in Overweight/Obese Subjects With MASLD/MASH Phase 2